Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’

Growth For Teriparatide Biosimilar Terrosa Expected To Slow In 2022

Executive Summary

Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.

You may also be interested in...



Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab

Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.

Gedeon Richter Pledges New Markets For Teriparatide Biosimilar

Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.

Gedeon Richter Provides Clues On Key Biosimilar Trial Dates

Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel